Do Masters Programs Include a Prescription for GLP-1 Medication? | Calibrate

What Calibrate's Masters Program Actually Covers

Calibrate Masters is a one-year metabolic health program that bundles physician-led medication management with behavioral coaching. The program is built around GLP-1 receptor agonists as its primary pharmacological tool, paired with lifestyle curriculum covering food quality, sleep, exercise, and emotional health. A prescription for a GLP-1 agent is part of the program's design, but it is conditional on a clinician determining that you meet established medical criteria.

How the Prescription Process Works

After enrollment, members complete an intake form covering weight history, comorbidities, current medications, and metabolic labs. A licensed physician or nurse practitioner then reviews that data. If your BMI is 30 or above, or if your BMI is 27 or above alongside a condition such as type 2 diabetes, hypertension, or dyslipidemia, you meet the FDA-cleared threshold for obesity pharmacotherapy as outlined in the FDA label for semaglutide 2.4 mg (Wegovy) [1].

The clinician then selects a specific GLP-1 agent. Semaglutide 2.4 mg (Wegovy) and tirzepatide 15 mg (Zepbound) are the two agents most commonly prescribed through programs structured like Calibrate Masters. Off-label use of semaglutide 1 mg (Ozempic) or tirzepatide 5/10/15 mg (Mounjaro) also occurs when insurance coverage or supply constraints favor those formulations [2].

What Happens If You Do Not Qualify

If a reviewing clinician determines you do not meet prescribing criteria, you will not receive a GLP-1 prescription through the program. Contraindications include a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, prior hypersensitivity to a GLP-1 receptor agonist, or active pancreatitis, per the FDA-approved labeling for semaglutide [1]. Pregnancy is also a contraindication; the Endocrine Society's 2015 obesity pharmacotherapy guidelines specify that pharmacological weight management should be discontinued in women who become pregnant [3].

Members who do not receive a prescription may still access the behavioral coaching curriculum, but the defining clinical feature of the Masters tier is the medication management component.

The Clinical Evidence Behind GLP-1 Prescribing in These Programs

GLP-1 receptor agonists have the most strong weight-loss trial data of any drug class currently available for obesity pharmacotherapy. Programs like Calibrate Masters anchor their clinical rationale to this evidence base, which is why understanding the trial data helps you interpret what a prescription through these programs can realistically achieve.

Semaglutide 2.4 mg: STEP-1 Trial

In STEP-1 (N=1,961 adults with BMI ≥30 or BMI ≥27 with comorbidity, no diabetes), semaglutide 2.4 mg subcutaneous once weekly produced a mean weight reduction of 14.9% from baseline at 68 weeks, versus 2.4% with placebo (P<0.001) [4]. Approximately 86% of participants in the semaglutide arm achieved at least 5% weight loss, compared with 32% in the placebo arm [4]. These figures come from the NEJM publication of STEP-1 and represent the evidence tier that FDA reviewers used when approving Wegovy in June 2021 [1].

Tirzepatide 15 mg: SURMOUNT-1 Trial

Tirzepatide, a dual GIP and GLP-1 receptor agonist, showed even larger reductions in SURMOUNT-1 (N=2,539 adults without diabetes, BMI ≥30 or BMI ≥27 with comorbidity). At 72 weeks, the 15 mg dose produced a mean weight loss of 20.9% versus 3.1% with placebo [5]. The FDA approved tirzepatide 2.5 to 15 mg (Zepbound) for chronic weight management in November 2023 [6]. Calibrate and similar programs began incorporating tirzepatide into prescribing protocols shortly after that approval.

Behavioral Coaching Augments Medication Effects

The STEP-1 trial included brief lifestyle counseling at every visit, which means the drug effect was measured on top of at least some behavioral support [4]. A 2021 meta-analysis in Obesity Reviews (18 RCTs, N=7,084) found that combining pharmacotherapy with structured lifestyle intervention produced 3.2 kg additional weight loss versus pharmacotherapy alone at 12 months [7]. Calibrate's four-pillar coaching model is designed to replicate that additive effect, targeting food quality, sleep duration, physical activity, and emotional health simultaneously.

GLP-1 Medications Available Through Calibrate-Style Programs

Semaglutide (Wegovy and Ozempic)

Semaglutide is a glucagon-like peptide-1 receptor agonist administered as a once-weekly subcutaneous injection. Wegovy (2.4 mg) carries an FDA indication specifically for chronic weight management in adults with BMI ≥30 or BMI ≥27 with at least one comorbidity [1]. Ozempic (0.5, 1.0, and 2.0 mg) is FDA-approved for glycemic control in type 2 diabetes and is frequently prescribed off-label for weight loss when Wegovy is unavailable or when a patient's insurer covers Ozempic but not Wegovy [2].

Dose titration for Wegovy follows a 16-week escalation schedule: 0.25 mg for weeks 1 through 4, 0.5 mg for weeks 5 through 8, 1.0 mg for weeks 9 through 12, 1.7 mg for weeks 13 through 16, then the 2.4 mg maintenance dose from week 17 onward [1]. Programs like Calibrate coordinate this titration schedule through their clinical team.

Tirzepatide (Zepbound and Mounjaro)

Tirzepatide targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. Zepbound is FDA-approved for weight management at doses of 2.5 mg through 15 mg once weekly [6]. Mounjaro carries a type 2 diabetes indication and is used off-label for weight loss in a similar pattern to the Ozempic/Wegovy situation [8].

Titration begins at 2.5 mg once weekly for four weeks, increasing by 2.5 mg increments every four weeks as tolerated, up to the maximum dose of 15 mg [6]. The most common adverse effects across the SURMOUNT program were nausea (31.0%), diarrhea (22.1%), vomiting (12.7%), and constipation (17.6%) at the 15 mg dose [5].

Compounded GLP-1 Agents

During periods of FDA-documented drug shortage, some telehealth programs have used compounded semaglutide or tirzepatide prepared by 503A or 503B pharmacies. The FDA removed semaglutide from its shortage list in March 2024 and tirzepatide in May 2024, triggering a compliance deadline for compounders [9]. Calibrate's prescribing team is responsible for ensuring that any dispensed medication meets current FDA compounding regulations, and members should ask explicitly which pharmacy fills their prescription and whether it is an FDA-registered facility.

How Calibrate Masters Compares to Other Program Tiers

Calibrate has offered multiple program configurations over time. The core distinction between tiers is the degree of clinician access, coaching frequency, and whether medication management is included. The Masters program sits at the top tier and includes all three components: physician-led medication management, weekly behavioral coaching, and access to metabolic lab ordering.

Lower tiers or entry-level offerings from Calibrate and comparable GLP-1 telehealth programs such as Ro, Noom Med, Found, and Form Health vary considerably. Some provide asynchronous clinician messaging only. Others offer medication management but no structured behavioral curriculum. A 2023 analysis published in JAMA Network Open found that structured obesity treatment programs combining pharmacotherapy with intensive behavioral intervention produced 5.0% greater weight loss at 12 months compared with medication-only models (P=0.003, N=4,311) [10]. That finding supports the clinical rationale for a bundled program design.

Insurance and Out-of-Pocket Costs

GLP-1 medications for weight loss carry list prices that exceed $1,000 per month in the United States. A 2023 report from IQVIA estimated that Wegovy's average net price after rebates was approximately $861 per month for cash-pay patients [11]. Calibrate's team works with members to pursue prior authorization through their insurance. The American Association of Clinical Endocrinology (AACE) 2023 clinical practice guidelines for obesity explicitly recommend that clinicians advocate for insurance coverage of anti-obesity medications as part of comprehensive care [12].

Medicare Part D currently does not cover anti-obesity medications, a gap the Treat and Reduce Obesity Act has sought to close for several years without yet passing [13]. Commercial insurance coverage rates for Wegovy and Zepbound vary by employer and plan, with estimates ranging from 30% to 55% of commercially insured lives having some anti-obesity medication benefit as of 2024.

Coaching Curriculum Details

The Masters behavioral curriculum runs in parallel with the medication titration period. Four content pillars are addressed: food (emphasis on protein adequacy and glycemic load), sleep (targeting 7 to 9 hours per night per CDC sleep guidelines [14]), exercise (progressive resistance and aerobic work aligned with the Physical Activity Guidelines for Americans, which recommend 150 minutes of moderate-intensity activity weekly [15]), and emotional health (stress regulation, motivation, and habit formation). Sessions are conducted via video or asynchronous messaging depending on the member's plan configuration.

Who Is a Good Clinical Candidate for a GLP-1 Prescription Through These Programs

Clinicians prescribing GLP-1 agents within any telehealth program apply the same FDA-cleared criteria used in brick-and-mortar practice. The Obesity Medicine Association's 2023 position statement specifies that obesity pharmacotherapy is appropriate when BMI meets threshold, other contributing causes of weight gain have been screened (hypothyroidism, Cushing syndrome, medication-induced weight gain), and the patient has no contraindications [16].

Lab Work Typically Required

Most programs require at minimum: fasting glucose or hemoglobin A1c, a lipid panel, TSH to screen for hypothyroidism, a comprehensive metabolic panel (CMP), and a complete blood count (CBC). Some programs also request a fasting insulin level and uric acid. These labs can be ordered through the program or submitted from a recent primary care visit.

Conditions That May Affect Eligibility

Candidates with a personal or family history of medullary thyroid carcinoma or MEN2 cannot receive any GLP-1 receptor agonist regardless of program tier, per FDA black-box warning language on all approved GLP-1 drugs [1] [6]. Active pancreatitis, severe gastroparesis, and a prior severe hypersensitivity reaction to a GLP-1 agent are also absolute contraindications. Candidates with diabetic retinopathy should inform their prescriber; SUSTAIN-6 observed a 76% relative increase in diabetic retinopathy complications with semaglutide 0.5/1.0 mg versus placebo (HR 1.76, 95% CI 1.11 to 2.78) in a cardiovascular outcomes trial of 3,297 patients with type 2 diabetes [17].

Candidates With Type 2 Diabetes

Adults with type 2 diabetes and overweight or obesity may benefit most from a GLP-1 receptor agonist because the drug addresses both glycemic control and weight. The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists as a preferred agent for adults with type 2 diabetes and BMI ≥27 who need weight management alongside glycemic control [18]. In this population, Ozempic or Mounjaro may be prescribed for the dual indication rather than the dedicated weight-management formulations.

What to Expect Month by Month in a Masters Program

Months 1 through 4: Titration and Baseline Establishment

This phase covers the dose escalation period. GI side effects, primarily nausea and occasional vomiting, are most prominent during titration. In STEP-1, nausea occurred in 44.2% of the semaglutide group versus 16.0% of the placebo group, with most cases rated mild to moderate [4]. Weight loss during titration is often modest; the bulk of the STEP-1 weight reduction occurred between weeks 20 and 68. Members also complete their initial coaching sessions and establish baseline dietary patterns during this phase.

Months 5 through 9: Sustained Weight Reduction

Once the maintenance dose is reached, weight loss typically accelerates. Calibrate's clinical team monitors for medication tolerability, adjusts the dose downward if side effects are unacceptable, and tracks metabolic markers. Lab rechecks are usually scheduled around week 16 and again at six months. The ADA recommends HbA1c monitoring every three months in patients initiating new diabetes pharmacotherapy [18], and similar intervals apply to metabolic monitoring in weight management programs.

Months 10 through 12: Maintenance Planning

The final program phase addresses what happens after the first year. Weight regain after GLP-1 discontinuation is well documented. The STEP-4 trial (N=803) found that participants who discontinued semaglutide 2.4 mg after 20 weeks of treatment regained two-thirds of their prior weight loss by week 68, while those who continued the drug maintained their reductions [19]. This finding underpins the Obesity Medicine Association's stance that obesity is a chronic disease requiring ongoing treatment, not a finite course [16].

Questions to Ask Before Enrolling in Any GLP-1 Program

Before signing up for Calibrate Masters or any competing telehealth program, ask the following directly:

• Which specific GLP-1 medications does your clinical team prescribe, and are they FDA-approved or compounded?
• Which pharmacy fills the prescription, and is it FDA-registered?
• What is the clinician's prescribing authority in my state, and will I have access to the same prescriber throughout the year?
• What is the total out-of-pocket cost if my insurance does not cover the medication?
• What happens to my prescription and coaching access if the program's model changes or the company discontinues a tier?
• Does the program offer a titration-down protocol if I experience intolerable side effects?

The Endocrine Society's clinical practice guidelines on obesity management in adults note that successful pharmacotherapy programs require "ongoing monitoring and dose adjustment" by a qualified clinician rather than a one-time prescribing encounter [3].